亚宝药业拟转让太原制药62%股权

Core Viewpoint - The company, Yabao Pharmaceutical, plans to sell 62% of its subsidiary, Taiyuan Pharmaceutical, to Shanxi Tongxiang Times Technology for a transaction price of 87.1887 million yuan, aiming to enhance operational efficiency and support future business expansion [1] Group 1: Transaction Details - The transaction involves the sale of 62% equity of Taiyuan Pharmaceutical to Tongxiang Technology for 87.1887 million yuan [1] - The company anticipates that the transaction will increase its total profit by approximately 59 million yuan in 2025, based on preliminary calculations [1] Group 2: Strategic Rationale - The sale is part of a comprehensive consideration for the company's future development, aimed at improving asset operation efficiency and reducing management costs [1] - The transaction is expected to enhance the company's ongoing operational capabilities and provide financial support for business expansion [1] Group 3: Employee and Management Changes - Employee placement at Taiyuan Pharmaceutical has been completed prior to the transaction [1] - Post-transaction, the management of Taiyuan Pharmaceutical will be nominated by Tongxiang Technology [1]